Dendreon

“Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has taken its first significant steps toward de-levering its balance sheet, announcing the divestiture of Dendreon and several dermatology brands for combined cash consideration of ~2.1 billion,” Canaccord Genuity’s Neil Marouka said...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares were seen soaring 9.3 percent on Tuesday after the company announced the sale of $2.1 billion in assets to raise money to pay down the company’s staggering $30 billion debt load. Divestitures Valeant sold skincare brands CeraVe, AcneFree and...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) soared higher by more than 13 percent Tuesday morning after the company agreed to sell multiple business units as part of an ongoing initiative to pay down its debt load, which has some Wall Street analysts deeply concerned. Valeant has agreed...

While Amgen (NASDAQ: AMGN) saw a sizable dip in short interest between the April 30 and May 15 settlement dates, short sellers piled on Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC). Among other leading biotechs and emerging pharmaceuticals, gains in the number of their shares sold...

Biotech stocks have proved to be volatile this year, and short sellers piled on Incyte (NASDAQ: INCY) between the April 15 and April 30 settlement dates. Pharmacyclics (NASDAQ: PCYC) and Regeneron Pharmaceuticals (NASDAQ: REGN) also saw double-digit percentage increases in the number of their...

Highlights on the earnings front this week include scheduled quarterly reports from Disney, Keurig Green Mountain, Pfizer and Whole Foods Market, which are expected to post year-over-year earnings gains. Analysts expect Tesla Motors to say its earnings declined, and for Groupon and SolarCity to...

In a period when many biotech stocks were slipping, short sellers moved on many of the leading biotech and emerging pharmaceuticals between the March 14 and March 31 settlement dates. But Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) were among those that bucked the...

After largely shying away in the previous period, short sellers found renewed interest in many of the leading biotech and emerging pharmaceutical companies between the February 28 and March 14 settlement dates. But Celgene (NASDAQ: CELG), Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC...

Short interest in most of the leading biotech and emerging pharmaceutical companies declined between the February 14 and February 28 settlement dates. But Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) bucked that trend. Short interest in Gilead...

The calendar page has turned, and the earnings season is all but done. But this week's earnings highlights will include quarterly reports from a few more retailers, such as Costco, Kroger, RadioShack and Staples, as well as some solar companies, including SolarCity and Trina Solar. Here is a...

Among the leading biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB) and BioMarin Pharmaceutical (NASDAQ: BMRN) saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates. Alexion Pharmaceuticals,...

Among the leading biotech and emerging pharmaceutical companies, Incyte (NASDAQ: INCY) and Pharmacyclics (NASDAQ: PCYC) saw the largest percentage declines in short interest between the January 15 and January 31 settlement dates. Short sellers shied away from Alexion Pharmaceuticals, Amgen, Biogen...

Among the leading biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) saw the most significant upswings between the December 31 and January 15 settlement dates. Gilead Sciences, Pharmacyclics and Regeneron...

The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December 13 and December 31 settlement dates. BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) led that trend. Short sellers also shied...